Cytokinetics Falls as Investors Appear to Take Profits Despite Recent Aficamten Progress

Cytokinetics (CYTK) is down 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff does not appear tied to a fresh negative company announcement on October 5. This could be because investors are taking profits after a recent stretch of positive aficamten news, while waiting for another clear catalyst from upcoming heart-failure and hypertrophic cardiomyopathy presentations.

Details:

On September 30, Cytokinetics said it launched ASPEN-HCM, a real-world study designed to track safety, effectiveness, and healthcare use for MYQORZO in obstructive hypertrophic cardiomyopathy.

On October 2, the company announced four presentations for the Heart Failure Society of America meeting on October 9-12, including new discussions tied to ACACIA-HCM and COMET-HF, which may have left traders in wait-and-see mode ahead of the event.

In late August, Cytokinetics highlighted positive Phase 3 ACACIA-HCM results in non-obstructive hypertrophic cardiomyopathy and said the data were published in a major medical journal, raising expectations that may now be hard to exceed in the near term.

Late-September insider filings showed executive stock sales, which can add pressure around biotech names even when they are routine or pre-arranged.

Sources:

Cytokinetics Investor Relations, SEC, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CYTK Insider Trading Activity

$CYTK insiders have traded $CYTK stock on the open market 44 times in the past 6 months. Of those trades, 0 have been purchases and 44 have been sales.

Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:

ROBERT I BLUM (President & CEO) has made 0 purchases and 14 sales selling 187,926 shares for an estimated $13,421,459.
ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 7 sales selling 87,782 shares for an estimated $6,535,077.
SUNG LEE (EVP, Chief Financial Officer) has made 0 purchases and 4 sales selling 66,882 shares for an estimated $5,389,145.
FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 12 sales selling 39,500 shares for an estimated $2,928,555.
JOHN T HENDERSON sold 20,000 shares for an estimated $1,519,400
B LYNNE PARSHALL has made 0 purchases and 2 sales selling 10,000 shares for an estimated $727,800.
WENDELL WIERENGA sold 4,032 shares for an estimated $302,400
EDWARD M. MD KAYE sold 2,933 shares for an estimated $223,171
ROBERT E LANDRY has made 0 purchases and 2 sales selling 2,000 shares for an estimated $146,790.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive CYTK Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CYTK Hedge Fund Activity

We have seen 316 institutional investors add shares of $CYTK stock to their portfolio, and 138 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 9,328,094 shares (+99.3%) to their portfolio in Q2 2026, for an estimated $794,660,327
FMR LLC removed 5,691,358 shares (-53.1%) from their portfolio in Q2 2026, for an estimated $484,846,788
BLACKROCK, INC. added 3,546,351 shares (+21.4%) to their portfolio in Q2 2026, for an estimated $302,113,641
AVORO CAPITAL ADVISORS LLC added 1,666,666 shares (+50.0%) to their portfolio in Q2 2026, for an estimated $141,983,276
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,603,442 shares (+inf%) to their portfolio in Q2 2026, for an estimated $136,597,223
JPMORGAN CHASE & CO added 1,588,895 shares (+inf%) to their portfolio in Q2 2026, for an estimated $135,357,965
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,565,781 shares (+inf%) to their portfolio in Q2 2026, for an estimated $133,388,883

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CYTK Congressional Stock Trading

Members of Congress have traded $CYTK stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$CYTK Price Targets

Multiple analysts have issued price targets for $CYTK recently. We have seen 10 analysts offer price targets for $CYTK in the last 6 months, with a median target of $106.5.

Here are some recent targets:

Leonid Timashev from RBC Capital set a target price of $117.0 on 07/07/2026
Ashwani Verma from UBS set a target price of $115.0 on 06/29/2026
Salim Syed from Mizuho set a target price of $118.0 on 06/24/2026
Serge Belanger from Needham set a target price of $102.0 on 06/17/2026
Eric Joseph from Citigroup set a target price of $99.0 on 05/19/2026
Tessa Romero from JP Morgan set a target price of $97.0 on 05/12/2026
Joseph Pantginis from HC Wainwright & Co. set a target price of $140.0 on 05/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.